Question 1

What is Tesofensine?

Accepted Answer

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed by NeuroSearch for Parkinson's disease and Alzheimer's. During neurological trials, researchers noticed significant weight loss as a side effect, pivoting the drug toward obesity treatment. Phase II trials showed remarkable results: up to 12.8% body weight loss over 6 months at the 1.

Question 2

What are the research benefits of Tesofensine?

Accepted Answer

Research on Tesofensine has investigated its potential effects in several areas, including: Up to 12.8% weight loss in Phase II (6 months); Oral administration — pill form, no injection; Novel mechanism — not GLP-1 based, could be complementary; Works through appetite suppression and satiety enhancement. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Tesofensine work?

Accepted Answer

Tesofensine inhibits the reuptake of serotonin, norepinephrine, and dopamine — the three major monoamine neurotransmitters involved in appetite regulation and reward. By increasing the availability of all three simultaneously, it reduces hunger, enhances satiety, and may reduce food-seeking behavior driven by the dopamine reward system. This triple action distinguishes it from SSRIs or SNRIs that affect only one or two monoamines.

Question 4

What is the FDA/legal status of Tesofensine?

Accepted Answer

Tesofensine is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of Tesofensine?

Accepted Answer

Based on available research, Tesofensine has been associated with the following in study settings: Increased heart rate (5-8 bpm in trials); Constipation; Potential for cardiovascular effects (main regulatory concern); Not a benign compound — CNS-active, affects multiple neurotransmitter systems. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Tesofensine?

Accepted Answer

Published research on Tesofensine can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Tesofensine" or its aliases (NS2330, Tesomet (with metformin)) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Tesofensine

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

Centrally Acting Agents for Obesity: Past, Present, and Future.

Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome.

New and emerging drug molecules against obesity.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer